Tag: Algernon Pharmaceuticals - Page 5 - Psychedelic Alpha

Read more about the article Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

Post published:December 8, 2021
Post category:Press Release

Read more about the article Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study

Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study

Post published:November 19, 2021
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study

Post published:November 1, 2021
Post category:Press Release

Read more about the article Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study

Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study

Post published:October 13, 2021
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose

Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose

Post published:September 7, 2021
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021

Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021

Post published:June 17, 2021
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke

Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke

Post published:May 27, 2021
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke

Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke

Post published:May 17, 2021
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

Post published:March 17, 2021
Post category:Press Release

Read more about the article Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)

Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)

Post published:March 1, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.